Literature DB >> 12768106

A review of studies on the effects of hemorrhagic shock and resuscitation on the coagulation profile.

Anna M Ledgerwood1, Charles E Lucas.   

Abstract

BACKGROUND: This study reports on the results of hemorrhagic shock (HS) plus resuscitation on the coagulation profile in severely injured patients and on the role of fresh frozen plasma (FFP) supplementation in a canine HS model. CLINICAL STUDIES: Primary hemostasis (platelet plug), secondary hemostasis (fibrin clot), and fibrinolysis were assayed in 22 injured patients who received an average of 21 units of packed red blood cells (PRBCs), 16.5 L crystalloid solution, and 1.25 L FFP during operation for control of bleeding. Measurements were obtained during operation and postoperatively at 5, 15, 36, and 84 hours and at 26 days. The platelet count during operation was 113,000/mm3, decreased to a nadir of 76,000/mm3 at 48 hours, and then increased to 563,000/mm2 by convalescence. Platelets were not given with resuscitation. The bleeding times and aggregation studies mirrored platelet levels until convalescence. HS led to significant reductions in fibrinogen (factor I), factor V, and factor VIII that normalized by day 1. The fibrinogen increased to supranormal levels by day 4 through day 26. Clotting times mirrored fibrinogen, factor V, and factor VIII levels. Fibrin split products were normal during operation and increased postoperatively through day 26. The increase in fibrin split products paralleled the increase in fibrinogen. EXPERIMENTAL STUDIES: The role of FFP supplementation in HS resuscitation was tested in two separate studies. After HS, the animals were resuscitated with shed blood and crystalloid; half the animals also received FFP. FFP did not improve the coagulation factors, fibrinogen and factors II, V, VII, and VIII. Thus, routine FFP supplementation for HS in humans was abandoned. This led to unexpected postoperative bleeding that in one instance caused death. Therefore, a second controlled study was used in which the FFP was given not only during blood volume restoration but also for an additional hour during continued ongoing controlled hemorrhage without shock. The second study demonstrated that the FFP prevented the reduction in coagulation factors compared with animals not receiving FFP. Clotting times paralleled coagulation protein levels. FFP is now used to supplement HS resuscitation in humans.
CONCLUSION: Resuscitation from hemorrhagic shock can be successfully implemented by restoration of blood loss with blood, crystalloid, and FFP added to maintain coagulation proteins.

Entities:  

Mesh:

Year:  2003        PMID: 12768106     DOI: 10.1097/01.TA.0000064513.59253.70

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  13 in total

1.  Clotting factor deficiency in early trauma-associated coagulopathy.

Authors:  Sandro B Rizoli; Sandro Scarpelini; Jeannie Callum; Bartolomeu Nascimento; Kenneth G Mann; Ruxandra Pinto; Jan Jansen; Homer C Tien
Journal:  J Trauma       Date:  2011-11

2.  Endocytosis of Red Blood Cell Microparticles by Pulmonary Endothelial Cells is Mediated By Rab5.

Authors:  Young Kim; William A Abplanalp; Andrew D Jung; Rebecca M Schuster; Alex B Lentsch; Erich Gulbins; Charles C Caldwell; Timothy A Pritts
Journal:  Shock       Date:  2018-03       Impact factor: 3.454

3.  Plasma first in the field for postinjury hemorrhagic shock.

Authors:  Ernest E Moore; Theresa L Chin; Michael C Chapman; Eduardo Gonzalez; Hunter B Moore; Christopher C Silliman; Kirk C Hansen; Angela Sauaia; Anirban Banerjee
Journal:  Shock       Date:  2014-05       Impact factor: 3.454

4.  A controlled resuscitation strategy is feasible and safe in hypotensive trauma patients: results of a prospective randomized pilot trial.

Authors:  Martin A Schreiber; Eric N Meier; Samuel A Tisherman; Jeffrey D Kerby; Craig D Newgard; Karen Brasel; Debra Egan; William Witham; Carolyn Williams; Mohamud Daya; Jeff Beeson; Belinda H McCully; Stephen Wheeler; Delores Kannas; Susanne May; Barbara McKnight; David B Hoyt
Journal:  J Trauma Acute Care Surg       Date:  2015-04       Impact factor: 3.313

5.  Coagulation studies in patients with orthopedic trauma.

Authors:  Kanchana Rangarajan; Arulselvi Subramanian; Jatin S Gandhi; Namit Saraf; Vijay Sharma; Kamran Farooque
Journal:  J Emerg Trauma Shock       Date:  2010-01

6.  A latent class model for defining severe hemorrhage: experience from the PROMMTT study.

Authors:  Mohammad H Rahbar; Deborah J del Junco; Hanwen Huang; Jing Ning; Erin E Fox; Xuan Zhang; Martin A Schreiber; Karen J Brasel; Eileen M Bulger; Charles E Wade; Bryan A Cotton; Herb A Phelan; Mitchell J Cohen; John G Myers; Louis H Alarcon; Peter Muskat; John B Holcomb
Journal:  J Trauma Acute Care Surg       Date:  2013-07       Impact factor: 3.313

7.  The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks.

Authors:  John B Holcomb; Deborah J del Junco; Erin E Fox; Charles E Wade; Mitchell J Cohen; Martin A Schreiber; Louis H Alarcon; Yu Bai; Karen J Brasel; Eileen M Bulger; Bryan A Cotton; Nena Matijevic; Peter Muskat; John G Myers; Herb A Phelan; Christopher E White; Jiajie Zhang; Mohammad H Rahbar
Journal:  JAMA Surg       Date:  2013-02       Impact factor: 14.766

8.  Activated clotting time of thrombelastography (T-ACT) predicts early postinjury blood component transfusion beyond plasma.

Authors:  Hunter B Moore; Ernest E Moore; Theresa L Chin; Eduardo Gonzalez; Michael P Chapman; Carson B Walker; Angela Sauaia; Anirban Banerjee
Journal:  Surgery       Date:  2014-06-02       Impact factor: 3.982

9.  Dynamic thromboembolic left ventricular outflow tract obstruction after aggressive procoagulant treatment in hemorrhagic shock: a case report.

Authors:  Vladimir Skrypnikov; Christoph Rosenthal; Steffen Weber-Carstens; Mario Menk; Martin Russ
Journal:  J Med Case Rep       Date:  2021-05-18

Review 10.  The contemporary role of blood products and components used in trauma resuscitation.

Authors:  David J Dries
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2010-11-24       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.